{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:16:43Z","timestamp":1794953803666,"version":"4.9.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["1357686"],"award-info":[{"award-number":["1357686"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["320185"],"award-info":[{"award-number":["320185"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.isci.2026.116932","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:13:15Z","timestamp":1786029195000},"page":"116932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma"],"prefix":"10.1016","volume":"29","author":[{"given":"Dimitrios","family":"Tsallos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemo","family":"Ikonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juho J.","family":"Miettinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muntasir Mamun","family":"Majumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuli","family":"Eldfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imre","family":"V\u00e4strik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alun","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Suvela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Dunphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Bazou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Lievonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raija","family":"Silvennoinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4324-8706","authenticated-orcid":false,"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116932_bib1","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","article-title":"Multiple myeloma: the (r)evolution of current therapy and a glance into future","volume":"105","author":"Gulla","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.116932_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cells9020287","article-title":"Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma","volume":"9","author":"Flynt","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.116932_bib3","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116932_bib4","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/life12060812","article-title":"Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup","volume":"12","author":"Wiedmeier-Nutor","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.isci.2026.116932_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70216","article-title":"European Myeloma Network Group Consensus Statement on the use of next-generation sequencing for prognostic stratification of newly diagnosed multiple myeloma","volume":"9","author":"Bolli","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.isci.2026.116932_bib6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood.2020008346","article-title":"del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116932_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.12","article-title":"Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker","volume":"7","author":"Chavan","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.116932_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116932_bib9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/cells14110776","article-title":"High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies","volume":"14","author":"De Novellis","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.116932_bib10","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116932_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2019004309","article-title":"Risk factors in multiple myeloma: is it time for a revision?","volume":"137","author":"Corre","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116932_bib12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.116932_bib13","doi-asserted-by":"crossref","first-page":"56338","DOI":"10.18632\/oncotarget.17630","article-title":"Identification of precision treatment strategies for relapsed\/refractory multiple myeloma by functional drug sensitivity testing","volume":"8","author":"Majumder","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.116932_bib14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.116932_bib15","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","article-title":"Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia","volume":"108","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.116932_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s43018-023-00544-9","article-title":"Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma","volume":"4","author":"Kropivsek","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2026.116932_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.2024024968","article-title":"Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial","volume":"145","author":"Kyt\u00f6l\u00e4","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116932_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.116932_bib19","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1101\/gad.340976.120","article-title":"p53 tetramerization: at the center of the dominant-negative effect of mutant p53","volume":"34","author":"Gencel-Augusto","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.isci.2026.116932_bib20","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/onc.2016.502","article-title":"Census and evaluation of p53 target genes","volume":"36","author":"Fischer","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.116932_bib21","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.116932_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2010.08360.x","article-title":"Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers","volume":"152","author":"Richardson","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.isci.2026.116932_bib23","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR\u2013Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.isci.2026.116932_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer Dependency Map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116932_bib25","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.isci.2026.116932_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/cancers11040475","article-title":"HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action","volume":"11","author":"Imai","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.116932_bib27","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41418-022-00999-w","article-title":"p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways","volume":"29","author":"Lindstr\u00f6m","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.isci.2026.116932_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1055589","article-title":"Hallmarks of cancer: The insulin-like growth factors perspective","volume":"12","author":"Werner","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.116932_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.775507","article-title":"The Cross Talk Between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses","volume":"9","author":"Cui","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.isci.2026.116932_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","article-title":"Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy","volume":"6","author":"Kang","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.isci.2026.116932_bib31","doi-asserted-by":"crossref","first-page":"12416","DOI":"10.1074\/jbc.M109.074211","article-title":"Chemotherapeutic drugs inhibit ribosome biogenesis at various levels","volume":"285","author":"Burger","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.isci.2026.116932_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.116932_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2021.103246","article-title":"The FAcilitates Chromatin Transcription (FACT) complex: Its roles in DNA repair and implications for cancer therapy","volume":"109","author":"Bhakat","year":"2022","journal-title":"DNA Repair"},{"key":"10.1016\/j.isci.2026.116932_bib34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature15251","article-title":"Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth","volume":"525","author":"Zhu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116932_bib35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.molcel.2011.11.022","article-title":"Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis","volume":"45","author":"Golomb","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2026.116932_bib36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 \u2014 from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116932_bib37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: mission accomplished?","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116932_bib38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.blre.2017.03.001","article-title":"p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell","volume":"31","author":"Tessoulin","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.isci.2026.116932_bib39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.isci.2026.116932_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2026.116932_bib41","article-title":"clusterProfiler 4.0: A universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.isci.2026.116932_bib42","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.isci.2026.116932_bib43","author":"Therneau"},{"key":"10.1016\/j.isci.2026.116932_bib44","author":"Kassambara"},{"key":"10.1016\/j.isci.2026.116932_bib45","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.116932_bib46","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2014.89","article-title":"Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia","volume":"28","author":"Kontro","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116932_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/leu.2016.202","article-title":"Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia","volume":"31","author":"Eldfors","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116932_bib48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1186\/s12864-017-4039-1","article-title":"The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia","volume":"18","author":"Kumar","year":"2017","journal-title":"BMC Genom."},{"key":"10.1016\/j.isci.2026.116932_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.clml.2019.01.003","article-title":"Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study","volume":"19","author":"Goldsmith","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226023102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226023102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:32:42Z","timestamp":1794951162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226023102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589004226023102"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116932","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116932"}}